Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension safety study of zagociguat in MELAS after TIS6463-203
2024-517514-15-00Phase 2Completed
- Sponsor
- Tisento Therapeutics
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of zagociguat in mitochondrial encephalomyopathies, sponsored by Tisento Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events. Started Dec 2025; status: completed.
02
Drugs
zagociguat
03
Conditions
mitochondrial encephalomyopathies
Beyond the preview
Go deeper on 2024-517514-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517514-15-00.